地中海贫血中红细胞生成调节的双刃剑效应
本文评述Zaidel等报告的1例输血依赖型β-地中海贫血患者在接受罗特西普后出现进行性脾大、血小板减少、溶血加重及网织红细胞和有核红细胞显著升高的矛盾临床场景,停药后迅速逆转。评述指出罗特西普通常促进晚期红系成熟,但罕见情况下似可触发或加重髓外造血和/或脾脏扣押,强调密切监测和认识个体易感性的重要性。
要点
- 罗特西普治疗输血依赖型β-地中海贫血可显著减少输血需求
- 罕见病例中罗特西普似可触发或加重髓外造血和/或脾脏扣押
- 用药期间需密切监测,需进一步研究明确机制和识别高危患者
核心结论
- 罗特西普通常增强晚期红系成熟,但在罕见病例中似可触发或加重髓外造血和/或脾脏扣押。
- 该报告强调密切监测和深入理解个体易感性对优化罗特西普在地中海贫血中安全使用的重要性。
- 需进一步研究以阐明潜在机制并识别罗特西普治疗期间发生髓外造血相关并发症的高危患者。
研究设计与样本
- 本文为对Zaidel等病例报告的评述,原文病例报告发表于Br J Haematol 2025; 206:1806-1810。
- 病例报告描述了1例输血依赖型地中海贫血患者在接受罗特西普后出现急性脾大、溶血和血小板减少。
主要发现
- 该病例中罗特西普治疗与进行性脾大、血小板减少、溶血加重以及网织红细胞和有核红细胞显著升高相关。
- 上述表现于停药后迅速逆转。
临床怎么用
- 作者强调密切监测和深入理解个体易感性对优化罗特西普在地中海贫血中安全使用的重要性。
- 作者指出需进一步研究以阐明潜在机制并识别罗特西普治疗期间发生髓外造血相关并发症的高危患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Luspatercept has emerged as a valuable therapeutic option for patients with transfusion-dependent β-thalassaemia, enabling significant reduction in transfusion requirements. In the report by Zaidel et al., a paradoxical clinical scenario is described in which treatment with luspatercept was associated with progressive splenomegaly, thrombocytopenia, increased haemolysis and a marked rise in reticulocytes and nucleated red blood cells, promptly reversible upon drug discontinuation. Luspatercept usually enhances late-stage erythroid maturation, but, in rare cases like this, seems to trigger or exacerbate extramedullary haematopoiesis (EMH) and/or splenic sequestration. The report underscores the importance of close monitoring and a deeper understanding of individual susceptibility to optimize the safe use of luspatercept in thalassaemia. Further studies are needed to clarify the underlying mechanisms and to identify patients at risk for EMH-related complications during luspatercept treatment. Commentary on: Zaidel et al. Acute splenomegaly, haemolysis, and thrombocytopenia following luspatercept initiation in a patient with transfusion-dependent thalassaemia: A case report. Br J Haematol 2025; 206:1806-1810.
引用
- Ricchi P. The double edge of erythropoietic modulation in thalassaemia. Br J Haematol. 2025. PMID: 40364548. doi:10.1111/bjh.20142
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。